Impaired absorption of rifabutin by concomitant administration of didanosine [3]

AIDS

Volumn 15, Issue 16, 2001, Pages 2203-2204

  Marzolini, Catia ^a   Chave, Jean Philippe ^a,b   Telenti, Amalio ^a   Brenas Chinchon, Laeticia ^c   Biollaz, Jérôme ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b La Source Hospital   (Switzerland)

^c BBR LTC Laboratories   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CYTOCHROME P450 3A4; DAPSONE; DIDANOSINE; ITRACONAZOLE; KETOCONAZOLE; LEVOFLOXACIN; LOPINAVIR; RIFABUTIN; RIFAMPICIN; RITONAVIR;

ADULT; CASE REPORT; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG EFFICACY; DRUG FORMULATION; DRUG SOLUBILITY; ENTERIC COATED TABLET; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MALE; PKA; PRIORITY JOURNAL; VIRUS LOAD;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIBIOTICS, ANTITUBERCULAR; DIDANOSINE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; INTESTINAL ABSORPTION; MALE; MIDDLE AGED; MYCOBACTERIUM INFECTIONS; REVERSE TRANSCRIPTASE INHIBITORS; RIFABUTIN;

EID: 0035834472     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200111090-00022     Document Type: Letter

References (4)

1. The clinical pharmacokinetics of rifabutin
2. The treatment of tuberculosis in HIV-infected persons
3. Pharmacokinetic interactions between Kaletra and other non-HIV drugs
4. Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients